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Abstract
Background: The role of genes involved in the control of progression from the G1 to the S phase
of the cell cycle in melanoma tumors in not fully known. The aim of our study was to analyse
mutations in TP53, CDKN1A, CDKN2A, and CDKN2B genes in melanoma tumors and melanoma
cell lines
Methods: We analysed 39 primary and metastatic melanomas and 9 melanoma cell lines by single-
stranded conformational polymorphism (SSCP).
Results: The single-stranded technique showed heterozygous defects in the TP53 gene in 8 of 39
(20.5%) melanoma tumors: three new single point mutations in intronic sequences (introns 1 and
2) and exon 10, and three new single nucleotide polymorphisms located in introns 1 and 2 (C to T
transition at position 11701 in intron 1; C insertion at position 11818 in intron 2; and C insertion
at position 11875 in intron 2). One melanoma tumor exhibited two heterozygous alterations in the
CDKN2A exon 1 one of which was novel (stop codon, and missense mutation). No defects were
found in the remaining genes.
Conclusion: These results suggest that these genes are involved in melanoma tumorigenesis,
although they may be not the major targets. Other suppressor genes that may be informative of
the mechanism of tumorigenesis in skin melanomas should be studied.
Background
The transition from phase G1 to S of the cell cycle is con-
trolled by sequential activation of cyclin/Cdk complexes
(Cyclin-dependent kinases) [1]. Active cyclin/Cdk com-
plexes phosphorylate and inactivate members of the retin-
oblastoma protein (Rb) family, which are negative
regulators of G1 and S-phase progression, leading to the
induction of E2F-regulated gene expression and cell pro-
liferation. Inhibitors of cyclin/Cdk complexes, by binding
to these complexes, negatively regulate cell cycle progres-
sion [2].
Two families of Cdk-inhibitors (CKI) control the actions
mediated by cyclin/Cdk complexes. p21 (also called
WAF1, and CDKN1A; MIM# 116899) [3] is the founding
member of the Cip/Kip family of CKI, which also includes
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p27 [4] and p57 [5]. Another class of Cdk inhibitors, the
so-called INK4 proteins (named for their ability to inhibit
cdk4), specifically target the cyclin D-dependent kinases
[6]. To date, four INK4 proteins have been identified: the
founding member p16INK4a (CDKN2A; MIM# 600160)
[7], and three other closely related genes designated
p15INK4b (CDKN2B; MIM# 600431) [8], p18INK4c (MIM#
603369) [9] and p19INK4d (MIM# 600927) [9].
In response to irradiation and chemotherapy, p53 protein
(MIM# 191170) is stabilised and mediates apoptosis and
cell cycle arrest. Whereas the mechanisms of p53-depend-
ent apoptosis are not well understood, p53-dependent
cell cycle arrest is known to be primarily mediated by p21,
a potent inhibitor of cyclin-dependent kinases that is
transactivated by p53 and p73 [10]. In addition to p21,
several other cell cycle regulators are induced by p53, such
as GADD45 and members of the 14-3-3 family [11].
The TP53 suppressor gene and Cdk-inhibitors such as
CDKN1A, CDKN2A, and CDKN2B are targets of tumoral
process in different types of tumors [12,13]. Mutations in
the TP53 gene occur frequently in skin tumors as basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC)
Table 1: Melanoma tumor samples
Tumor aHistopathology bBreslow (mm) Clark cTumor sample
M3 SSM 5.5 IV P
M 4 a N M --S m
M 4 b N M --S m
M 5 ---P
M 6 ---N m
M7a SSM 4 IV Nm
M7b SSM 4 IV Sm
M8 SSM 0.5 II P
M13 SSM 3.9 III P
M18 NM 5 V Nm
M 1 9 ---N m
M21 SSM 3.5 III P
M 2 2 ---N m
M23 SSM 9 IV Nm
M 2 4 A L M --N m
M31 SSM 3 IV Nm
M 3 2 ---N m
M34 SSM 16 V P
M37 SSM 1.8 III Nm
M38 NM 9 V P
M40 NM 3.4 IV Nm
M42 NM 1.5 IV Nm
M43 SSM 2.5 IV P
M44a NM 10 IV P
M44b NM 10 IV Sm
M 4 5 ---N m
M 4 6 ---P
M 4 9 ---P
M 5 0 ---N m
M 5 2 L M M --N m
M 5 3 ---N m
M55 ALM - V Nm
M56 LMM 1 III P
M59 NM 10.1 III P
M60 SSM 3 III P
M 7 1 N M --P
M72 SSM 0.6 III P
M73 SSM 2.5 III P
M 7 4 ---N m
aSSM (superficial spreading melanoma), NM (nodular melanoma), LMM (lentigo maligna melanoma), ALM (acral lentigo melanoma). bBreslow vertical 
tumor thickness. cP, primary melanoma; Nm, lymph node metastases; Sm, subcutaneous metastases.BMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
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[14]. In human melanoma, TP53 mutations are appar-
ently not commonly detected [15,16], and consist mainly
of C to T transitions located on dipyrimidine sites origi-
nated by UV radiation [17]. In contrast, CDKN2A is
deleted or mutated in human sporadic melanomas and
derived cell lines [18], and it appears to be the predispos-
Table 2: Oligonucleotide primer sequences
TP53, exons 2 to 11 (GeneBank Accession: X54156)
Exon Primer Sequence 5'→ 3' Fragment (bp)
PU2 (sense) TCCTCTTGCAGCAGCCAGACTGC
PD3 (antisense) AACCCTTGTCCTTACCAGAACGTTG
4 PU4 (sense) CACCCATCTACAGTCCCCCTTGC 307
PD4 (antisense) CTCAGGGCAACTGACCGTGCAAG
5 PU5 (sense) CTCTTCCTACAGTACTCCCCTGC 211
PD5 (antisense) GCCCCAGCTGCTCACCATCGCTA
6 PU6 (sense) GATTGCTCTTAGGTCTGGCCCCTC 182
PD6 (antisense) GGCCACTGACAACCACCCTTAACC
7 PU7 (sense) GTGTTATCTCCTAGGTTGGCTCTG 139
PD7(antisense) CAAGTGGCTCCTGACCTGGAGTC
8 PU8 (sense) ACCTGATTTCCTTACTGCCTCTTGC 200
PD8 (antisense) GTCCTGCTTGCTTACCTCGCTTAC
9 PU9 (sense) GCCTCTTTCCTAGCACTGCCCAAC 102
PD9 (antisense) CCCAAGACTTAGTACCTGAAGGGTG
10 PU10 (sense) TGTTGCTGCAGATCCGTGGGCGT 130
PD10 (antisense) GAGGTCACTCACCTGGAGTGAGC
11 PU11 (sense) TGTGATGTCATCTCTCCTCCCTGC 153
PD11 (antisense) GGCTGTCAGTGGGGAACAAGAAGT
CDKN1A, exon 2 (GeneBank Accession: AF497972)
p21-L1 (sense) GATGTCCGTCAGAACCCATG 258
p21-R1 (antisense) TGCCTCCTCCCAACTCAT
p21-L2 (sense) ATGAGTTGGGAGGAGGCA 181
p21-R2 (antisense) ATGCTGGTCTGCCGCCGTT
CDKN2A, exons 1(GeneBank Accession: U12818) and 2 (GeneBank Accession: U12819)
1 MTS1-L1 (sense) GAAGAAAGAGGAGGGGCTG 340
MTS1R1 (antisense) GCGCTACCTGATTCCAATTC
2 p16-L2 (sense) GTCATGATGATGGGCAGC 307
p16-R2 (antisense) CTGAGGGACCTTCCGCG
CDKN2B, exon 2 (GeneBank Accession: AF513858)
MTS2-L2 (sense) TAAGTTTAACCTGAAGGTGG 500
MTS2-R (antisense) GGGTGGGAAATTGGGTAAGBMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
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ing mutation in some familial melanoma kindreds [19]. A
low incidence of mutations has been described for the
CDKN2B gene in sporadic melanoma tumors [20]; how-
ever, no structural defects have been detected in the
CDKN1A gene in human melanoma.
In order to investigate the role of the genes involved in the
control of G1/S phase cell cycle progression in human
melanomas, the aim of our study was to determine the
presence of mutations in TP53, CDKN1A, CDKN2A and
CDKN2B genes in primary and metastatic melanomas
and melanoma cell lines.
Methods
Tumor samples
Thirty-nine specimens of skin melanoma were obtained
from the Department of Surgery at the Hospital Universi-
tario San Cecilio of Granada, Spain (Table 1). Melanoma
tumors were dissected from normal tissues in fresh sam-
ples under sterile conditions, and tumor tissues were fro-
zen in liquid nitrogen and stored at -80°C until DNA
isolation. DNA was obtained from peripheral blood from
each patient. The following 9 melanoma cell lines were
included in this study: MZ2-MEL, MEL-3.0, MEL-2.2, and
Mi-13443 were provided by Dr. T. Boon (Ludwig Institute
of Cancer Research, Brussels, Belgium); and M31-L, M42-
L, M52-L, M34-L, and M59-L were established in our lab-
oratory as described previously [21]. The clinical and
pathological characteristics of primary melanoma tumors
and derived metastases are described in Table 1. Of the 39
tumors studied, 14 were primary (36%) while the rest
were metastatic (18 ganlionar metastases and 4 subcuta-
neous metastases).
DNA isolation
DNA was isolated from tumor samples and peripheral
blood lymphocytes with the MicroTurboGen Genomic
DNA Isolation Kit (Invitrogen, San Diego, California) and
the Quiagen kit (Wetsburg, Leusden, The Netherlands)
respectively.
Mutation analysis of TP53, CDKN1A, CDKN2A, and 
CDKN2B genes
Point mutations were detected by changes in single-
stranded conformational polymorphism (SSCP) of DNA
amplified by polymerase chain reaction (PCR), as
described by Orita et al [22] with slight modifications
[23]. TP53 exons 2–11, CDKN1A exon 2, CDKN2B exon
2, and CDKN2A exons 1–2 were amplified. The sequences
of the primers used and fragments (bp) amplified are
described in Table 2. All TP53 primers used were provided
by Clontech (Human p53 Amplier Panels, Palo Alto, CA).
A portion of TP53 intron 1, exon 2, intron 2 and exon 3
was amplified using the primers PU2 (sense) and PD3
(antisense). CDKN1A exon 2 was amplified in two over-
lapping fragments with the following primer pairs: p21-
L1/p21-R1 and p21-L2/p21-R2 (Table 2).
Amplifications were performed using 100 ng genomic
DNA and α 32P-dCTP (300 Ci/mmol) in a final volume of
25 µl. The PCR conditions for TP53 exons 2–11 were as
follows: 35 cycles at 95°C/30 s, 66°C/45 s and 72°C/1.5
min, with a 10 min extension after the last cycle. CDKN1A
exon 2, CDKN2B exon 2, and CDKN2A exons 1–2 were
amplified under the same PCR conditions: in a touch-
down PCR procedure the temperature of the reaction was
lowered by 1°C every second cycle from 68°C to 60°C, at
which temperature 30 cycles were carried out.
Amplified samples (2.5 µl) were mixed with 9 µl of
sequencing stop solution (USB, Cleveland, OH, USA), 1.5
µl of 0.08 N NaOH, and 15 µl of 0.1% SDS, denatured for
10 min at 95°C, and the samples were quickly cooled in
dry ice. Samples of 3 µl were loaded onto a 6% non-dena-
turing acrylamide gel containing 10% glycerol, and run at
room temperature for 4 h at 22 W. Gels were dried at
80°C under vacuum and exposed to x-ray films for 4–16
h.
DNA sequencing
Asymmetric PCR reactions were purified from agarose gels
and reamplified. PCR products were cloned in the PCR 4-
TOPO vector using the TOPO TA Cloning Kit for sequenc-
ing (Invitrogen, Groningen, The Netherlands). After trans-
formation several clones were picked and sequenced.
Sequence analysis was carried out with the Sequenase
DNA Sequencing kit (USB), using α 35S-dATP (DuPont-
NEN, Boston, MA) incorporation. Aliquots of the reaction
mixture were run on a 6% denaturing acrylamide gel.
Results
Intronic single nucleotide polymorphisms and 
heterozygous point mutations in the TP53 gene
Of a total of 39 melanoma tumors and 9 melanoma cell
lines studied by PCR-SSCP, we detected defects in the
TP53 gene in 8 of 39 (20.5%) melanoma tumors, and did
not find any alteration in melanoma cell lines (Table 3).
Mutation analysis showed three novel heterozygous sin-
gle point mutations in the TP53 sequence and four differ-
ent single nucleotide polymorphisms, three of which have
not been described to date. All novel single point
mutations and polymorphisms were compared with the
IARC (International Agency for Research on Cancer) TP53
Mutation Database http://www-p53.iarc.fr/index.html.
The G to C transversion found at position 11827 in TP53
intron 2 in M4, M7, M38 and M53 melanoma tumors was
previously described by Oliva et al [24] (Figure 1). In this
study, we found 3 new single nucleotide polymorphisms
located at intron 1 and 2 of the TP53 gene when we com-BMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
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pared genomic DNA from melanoma tumors and DNA
from autologous PBLs with control PBLs (Figure 1). The C
to T transition was found at position 11701 of TP53
intron 1 in melanoma tumors M53 and M71 (Figure 2); a
C insertion was found at position 11818 of TP53 intron 2
in melanoma tumors M7, M42, M53 and M71; and a C
insertion was found at position 11875 of TP53 intron 2 in
melanoma tumors M7, M38, M42, M53, and M71 (Table
3).
A heterozygous C deletion in TP53 exon 10 at position
172628 produced a stop codon and truncated the p53
protein in melanoma tumor M34. Melanoma tumors
M42 and M43 showed heterozygous single point muta-
tions at TP53 introns 1 and 2. The C to T transition at posi-
tion 11701 in intron 1, observed in melanoma tumor
M42, contrasted with the absence of this transition in
autologous PBLs. In contrast, a C insertion was found at
position 11818 in intron 2 of TP53 in autologous PBLs,
but this polymorphism was not seen in melanoma tumor
M43 (Tale 3).
Mutation analysis of CDKN1A, CDKN2A, and CDKN2B 
Cdk (Cyclin-dependent kinases) inhibitors genes
Two heterozygous alterations in CDKN2A exon 1 were
observed in melanoma tumor M13 one of which novel,
whereas no defects were seen in the CDKN1A and
CDKN2B genes. The G to A transition produced a stop
codon at position 149 [25]; and the novel T to C transi-
tion at position 298 resulted in substitution of proline for
leucine (Table 3).
Discussion
Polymorphisms versus mutations in the TP53 gene in 
human melanoma
The major carcinogenic agent in most skin cancers is well
established as solar ultraviolet light [26]. This is absorbed
in DNA, with the formation of UV-specific dipyrimidine
photoproducts. About 50% of all skin cancers exhibit
TP53 mutations [17], and these mutations are character-
ised by a specific signature attributed to the UVB part of
the solar spectrum. The impact of UVB radiation can be
clearly inferred from the characteristic point mutations in
TP53 found in human SCC and BCC, consisting of C to T
or CC to TT transitions at dipirymidine sites [27]. These
findings contrast with the situation in human melano-
mas, in which TP53 mutations are not commonly
detected. The results of the present study support earlier
findings that such mutations are indeed infrequent in this
type of tumour. The influence of UVB radiation in these
mutations is not clear. TP53 mutations in primary
melanoma tumors induced by UVB radiation have been
described previously by Zerp et al [16]. However, in the
tumors examined in our study we did not find TP53
alterations originated by UVB radiation (Table 3). In con-
trast, we detected two new mutations located in intronic
sequences (C deletion at position 11818 in intron 2, and
C to T transition at position 11701 in intron 1) (Table 3)
and the novel C deletion at codon 350 of TP53 exon 10
which produced a stop codon and truncated protein.
More than 90% of the mutations reported in non-
melanoma skin cancers and different types of tumors are
clustered between exons 4 and 8 [28]. This region is highly
conserved throughout evolution and contains the DNA-
binding domain of p53, which is essential for its activity
[29]. This contrasts with the trans-activation domain
(encodes by exons 2 and 3) and the regulatory region
(encodes by exons 9 to 11), where few mutations have
been described. Therefore, the TP53 single nucleotide pol-
Table 3: Single nucleotide polymorphisms (SNPs) and mutations 
(M) in TP53, CDKN1A, CDKN2A, and CDKN2B genes
TP53
Tumor
M4 11827G>C (intron 2) (SNP)
11875insC (intron 2) (SNP)
M7 11827G>C (intron 2) (SNP)
11818insC (intron 2) (SNP)
11875insC (intron 2) (SNP)
M38 11827G>C (intron 2) (SNP)
11875insC (intron 2) (SNP)
M42 11701C>T (intron 1) (M)
11818insC (intron 2) (SNP)
11875insC (intron 2) (SNP)
M43 11875insC (intron 2) (SNP)
11818delC (intron 2) (M)
M53 11701C>T (intron 1) (SNP)
11827G>C (intron 2) (SNP)
11818insC (intron 2) (SNP)
11875insC (intron 2) (SNP)
M71 11701C>T (intron 1) (SNP)
11818insC (intron 2) (SNP)
11875insC (intron 2) (SNP)
M34 17628delC (codon 350: CTC→ CTA, exon 10), stop 
codon at the beginning of exon 11 (M)
CDKN2A, exon 1
M13 g.149G>A, TGG (Trp)→ TGA (stop codon) (M)
g.298T>C, CTC (Leu)→ CCC (Pro) (M)
CDKN1A, and CDKN2B No alterations foundBMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
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ymorphisms detected in these melanoma tumors appear
to be their most frequent characteristic.
At least twelve intronic polymorphisms have been
described in the human TP53 gene. These include
between others a VNTR (variable number tandem repeat)
region [30] and HaeIII restriction fragment length
polymorphism (RFLP) [31] in intron 1, a G to C transver-
sion in intron 2 [24], a 16 bp duplication in intron 3 (5'-
gacctggagggctggg-3') [32], a MspI RFLP in intron 6 (G to A
transition at 61 bp downstream of exon 6) [33,34], a G to
C transversion at 37 bp upstream to exon 7 [35], an ApaI
RFLP in intron 7 [36], and A to T transversion in intron 10
[37]http://www.iarc.fr/p53/polymorphisms. The
melanoma tumors and melanoma cell lines studied here
showed the G to C transversion at position 11827 of TP53
intron 2, previously described by Oliva et al [24] in four
melanoma tumors (M4, M7, M38, and M53), and three
new single nucleotide polymorphisms: C to T transition at
position 11701 of TP53 intron 1; C insertion at position
11818 of TP53 intron 2; and C insertion at position
11875 of TP53 intron 2 (Figure 1). Moreover, we found
three new heterozygous single point mutations in the
TP53 gene (Table 3), the incidence of mutations detected
in the TP53 gene accounted for only 7.7% (3 of 39
melanoma tumors) in contrast to 18% (7 of 39
melanoma tumors) of single nucleotide polymorphisms
found in these tumors.
Associations between cancer phenotypes and inherited
TP53 intronic polymorphisms have been observed in
studies of epithelial cancers including ovarian, breast,
colon, thyroid, nasopharyngeal, lung cancer, and thyroid
[34,35,38-40]. The frequency of G to C transition at posi-
tion 11827 in intron 2 of TP53 gene (3 of 39 melanoma
tumors, 7.7%) is low compared to the frequency of the A1
allele (G to C transition at position 11827) described pre-
viously in Caucasian individuals [41]. The polymor-
phisms that we detected in these melanoma tumors may
play a role in the risk of developing skin melanoma in
these patients.
Single nucleotide polymorphisms detected in intron 1 and intron 2 sequences of the TP53 gene in melanoma tumors Figure 1
Single nucleotide polymorphisms detected in intron 1 and intron 2 sequences of the TP53 gene in melanoma tumors. Each pol-
ymorphism and its positions are indicated by an asterisk (*), to determinate the presence of the polymorphisms the DNA 
sequence from melanoma tumors and autologous PBLs were compared with control PBLs.
TCC TCT TGC AGC AGC CAG ACT GCC* ttc cgg gtc act gcc atg gag gag ccg cag tca gat cct
T
agc gtc gag ccc cct ctg agt cag gaa aca ttt tca gac cta tgg aaa ct g tga gtg gat cca ttg gaa ggg
cag gcC* acc acc ccG* acc cca acc cca gcc ccc tag cag aga cct gtg gga agc gaa aat tcA* tgg
insCC insC
gac tga ctt tct gct ctt gtc ttt cag act tcc tga aaa CAA CGT TCT G GT AAG GAC AAG GGT T
PD3 Exon 3
Exon 2 PU2 11701
11818 11827 11875BMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
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Alterations in cyclin-Cdk inhibitors: CDKN1A, CDKN2A, 
and CDKN2B
Our results revealed the low incidence of mutations in
cyclin-Cdk inhibitors in both melanoma tumors and
melanoma cell lines. We detected only two mutations in
exon 1 of the CDKN2A gene, both in melanoma tumor
M13: G to A transition at position 149 producing a stop
codon [25], and the novel missense mutation Leu298 (leu-
cine →  proline). The low incidence of CDKN2A muta-
tions found in primary melanomas is concordant with
previous reports [42,43]. In contrast, melanomas cell lines
show a high incidence of mutations in CDKN2A, with
homozygous deletion being the main mechanism of alter-
ation [42]. These results suggest that in sporadic
melanoma tumors, CDKN2A might not be a target of
mutation, whereas in familial melanoma this mutation
accounts for approximately 10% of all cases of tumors.
Conclusion
We conclude that although none of the cell cycle regula-
tors analysed here can be singled out as a main mutation
target for melanoma tumorigenesis, G1/S checkpoint
defects are one of the significant factors in the develop-
ment of melanoma tumors. However, this influence
appear to be low in tumors, unlike the situation in
melanoma cell lines. Other suppressor genes will be
investigated to identify the main targets in the pathogene-
sis of melanoma.
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New single nucleotide polymorphism found in intron 1 of the TP53 gene (C>T transition) at position 11701 Figure 2
New single nucleotide polymorphism found in intron 1 of the TP53 gene (C>T transition) at position 11701. (A) PCR-SSCP 
analysis of melanoma tumors. The arrow indicates the shifted band in melanoma tumor M71. DC, denaturing control; NDC, 
non-denaturing control. (B) DNA sequence of melanoma tumor M71 and autologous PBLs showing the C to T base change 
(shown by an asterisk *) at position 11701 compared with control PBLs.
3‘
c
t
g
g
g
c
c
t
t
T* (11701)
c
g
t
c
a
g
a
5'
3‘
c
t
g
g
g
c
c
t
t
C* (11701)
c
g
t
c
a
g
a
5'
GA T C GA T C
Control PBLs Tumor (M71) and
autologous PBLs
N
D
C
D
C
M
3
M
7
1
M
8
3
M
2
2
M
2
3
M
2
4
M
3
1
M
3
2
M
3
4
M
3
7
M
4
0
M
4
4
a
M
5
0
M
5
5
ABBMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
Page 8 of 9
(page number not for citation purposes)
Authors' contributions
JLS carried out the molecular genetic studies of SSCP and
DNA sequencing. CMC participated in the manuscript
drafted. SS participated in the design of the study. MALN
participated in the design, coordination and helped to
draft the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This study was supported by FISS grant 021542 from the Spanish Ministry 
of Health. We thank K. Shashok for checking the use of English in the 
manuscript.
References
1. Ekholm SV, Reed SI: Regulation of G1 cyclin-dependent kinases
in the mammalian cell cycle. Curr Opin Cell Biol 2000, 12:676-684.
2. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative
regulators of G1-phase progression.  Genes Dev 1999,
13:1501-1512.
3. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin
D, Mercer WE, Kinzler K, Vogelstein B: WAF1, a potential medi-
ator of p53 tumor suppression. Cell 1993, 75:817-825.
4. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin/cdk
protein kinase activity, is related to p21. Cell 1994, 78:67-74.
5. Lee MH, Reynisdottir I, Massagué J: Cloning of p57KIP2, a cylin-
dependent kinase inhibitor with unique domain structure
and tissue distribution. Genes Dev 1995, 9:639-649.
6. Ruas M, Peters G: The p16INKa/CDKN2A tumor suppressor and
its relatives. Biochim Biophys Acta 1998, 1378:F115-F177.
7. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell
cycle control causing specific inhibition of cyclin D/CDK4.
Nature 1993, 366:704-707.
8. Hannon GJ, Beach D: p15INK4b is a potential effector of TGFβ -
induced cell cycle arrest. Nature 1994, 371:257-261.
9. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ: Novel INK4 pro-
teins, p19 and p18, are specific inhibitors of the cyclin D-
dependent kinases CDK4 and CDK6.  Mol Cell Biol 1995,
15:2672-2681.
10. Lohrum M, Vousden K: Regulation and function of the p53-
related proteins: same family, different rules. Trends Cell Biol
2000, 10:197-202.
11. Rich T, Allen RL, Wyllie AH: Defying death after DNA damage.
Nature 2000, 407:777-783.
12. Yonghas T, Quian H, Chuanyuan L, Yandell DW: Deletions and
point mutations of p16, p15 genes in primary tumors and
tumors cell lines. Chin Med Sci J 1999, 14:200-205.
13. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R,
Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiga T,
Hayashi Y: Alterations of the p53, p21, p16, p15 and RAS
genes in childhood T-cell acute lymphoblastic leukemia. Leuk
Res 1999, 23:115-126.
14. Moles JP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, Bas-
set-Seguin N: p53 gene mutations in human epithelial skin
cancers. Oncogene 1993, 8:583-588.
15. Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS,
Helander S, Pittelkow MR, Sommer SS, Kovach JS: Overexpression
and mutations of p53 in metastatic malignant melanomas.
Int J Cancer 1996, 67:313-317.
16. Zerp SF, Elsas van A, Peltenburg LTC, Schrier PI: P53 mutations in
human cutaneous melanoma correlate with sun exposure
but are not always involved in melanogenesis. Br J Cancer 1999,
79:921-926.
17. Giglia-Mari G, Sarasin A: TP53 mutations in human skin
cancers. Hum Mutat 2003, 21:217-228.
18. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek
J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit
frequently altered in melanoma pathogenesis.  Cancer Res
1996, 56:5475-5483.
19. Liggett WH Jr, Sidransky D: Role of the p16 tumor suppressor
gene in cancer. J Clin Oncol 1998, 16:1197-1206.
20. Matsumura Y, Nishigori C, Yagi T, Imamura S, Takebe H: Mutations
of p16 and p15 tumor suppressor genes and replication
errors contribute independently to the pathogenesis of spo-
radic malignant melanoma.  Arch Dermatol Res 1998,
290:175-180.
21. Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J:
Generation of human-melanoma-specific T lymphocyte
clones defining novel cytolytic targets with panels of newly
established melanoma cell lines.  Cancer Immunol Immunother
1995, 41:71-76.
22. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detec-
tion of point mutations and DNA polymorphisms using
polymerase chain reaction. Genomics 1989, 5:874-879.
23. Prosser J: Detecting single-base mutations.  TIBTECH 1993,
11:238.
24. Oliva MR, Saez GT, Latres E, Cordon-Cardo C: A new polymor-
phic site in intron 2 to TP53 characterizes LOH in human
tumors by PCR-SSCP. Diagn Mol Pathol 1995, 4:54-58.
25. Holland EA, Schmid H, Kefford RF, Mann GJ: CDKN2A
(P16(INK4a)) and CDK4 mutation analysis in 131 Australian
melanoma probands: effect of family history and multiple
primary melanomas.  Genes Chromosomes Cancer 1999,
25:339-348.
26. Cleaver JE, Crowley E: UV damage, DNA repair and skin
carcinogenesis. Front Biosci 2002, 7:d1024-1043.
27. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Siman JA, Halp-
erin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE: Mutation
hotspots due to sunlight in the p53 gene of non-melanoma
skin cancers. Proc Natl Acad Sci USA 1993, 90:4216-4220.
28. Soussi T: The p53 tumour suppressor gene: a model for
molecular epidemiology of human cancer. Mol Med Today 1996,
2:32-37.
29. Mendoza-Rodriguez CA, Cerbon MA: Tumor suppressor gene
p53: mechanisms of action in cell proliferation and death. Rev
Invest Clin 2001, 53:266-273.
30. Hahn M, Serth J, Fislage R, Wolfes H, Allhoff E, Jonas V, Pingoud A:
Polymerase chain reaction detection of a highly polymorphic
VNTR segment in intron 1 of the human p53 gene. Clin Chem
1993, 39:549-550.
31. Ito T, Seyama T, Hayashi T, Mizuno T, Iwamoto KS, Tsuyama N, Dohi
K, Nakamura N, Akiyama M: Hae III polymorphism in intron 1 of
the human p53 gene. Human Genet 1994, 93:222.
32. Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B: Simple
sequence repeat polymorphism within the p53 gene. Onco-
gene 1993, 8:1703-1705.
33. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rother V: A novel
polymorphism in intron 6 of the human p53 gene: a possible
association with cancer predisposition and susceptibility.
DNA Cell Biol 1995, 14:983-990.
34. Mavridou D, Gornall R, Campbell IG, Eccles DM: TP53 intron 6
polymorphism and the risk of ovarian and breast cancer. Br J
Cancer 1998, 77:676-677.
35. Hillebrandt S, Streffer C, Demidchik EP, Biko J, Reiners C: Polymor-
phisms in the p53 gene in thyroid tumours and blood sam-
ples of children from areas in Belarus.  Mutat Res 1997,
381:201-207.
36. Prosser J, Condie A: Biallelic ApaI polymorphism of the human
p53 gene (TP53). Nucleic Acids Res 1991, 19:4799.
37. Buller RE, Skilling JS, Kaliszewski S, Niemann T, Anderson B:
Absence of significant germline p53 mutations in ovarian
cancer patients. Gynecol Oncol 1995, 58:368-374.
38. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L,
Beckman G: p53 germline haplotypes associated with
increased risk for colorectal cancer.  Carcinogenesis 1995,
16:1461-1464.
39. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Sei-
dergard J, Tornling G, Beckman G, Beckman L: p53 polymorphisms
and haplotypes in lung cancer.  Carcinogenesis 1995,
16:2233-2236.
40. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G: p53
polymorphisms and haplotypes in nasopharyngeal cancer.
Hum Hered 1996, 46:49-54.
41. Ge H, Lam WK, Lee J, Wong MP, Fu KH, Yew WW, Lung ML: Detec-
tion and evaluation of p53 intron 2 polymorphism in lung
carcinomas in Hong Kong. Int J Cancer 1996, 69:120-124.
42. Ruiz A, Puig S, Lynch M, Castel T, Estivell X: Retention of the
CDKN2A locus and low frequency of point mutations in pri-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:36 http://www.biomedcentral.com/1471-2407/5/36
Page 9 of 9
(page number not for citation purposes)
mary and metastatic cutaneous malignant melanoma. Int J
Cancer 1998, 76:312-316.
43. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen
M, Punnonen K, Jansen CT, Hemminki K, Pyrhonen S: Analysis of
G(1)/S checkpoint regulators in metastatic melanoma. Genes
Chromosomes Cancer 2000, 28:404-414.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/36/prepub